Alzheimer’s Disease Diagnostic Market Forecast To Reach $11.89 Billion By 2030: Key Trends Explained
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Alzheimer’s Disease Diagnostic Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The market for Alzheimer’s disease diagnostics has experienced significant expansion recently. Its valuation is projected to increase from $7.26 billion in 2025 to $8.03 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 10.6%. This historical growth is primarily due to factors such as the increasing incidence of Alzheimer’s disease, greater recognition of neurodegenerative conditions, wider use of MRI and PET imaging techniques, the expansion of diagnostic centers and hospitals, and enhanced investment in research for cognitive assessment.
The market for Alzheimer’s disease diagnostics is projected to experience swift expansion over the coming years. This market is set to reach $11.89 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.3%. This anticipated growth during the forecast timeframe stems from several factors, including the advancement of new biomarkers and imaging tracers, the incorporation of AI for earlier detection, increased government and private investment in Alzheimer’s research, the proliferation of personalized medicine programs, and an uptick in multi-center clinical studies. Key trends for this period encompass a greater uptake of biomarker-driven diagnostics, enhanced utilization of neuroimaging methods for early discovery, an increase in cognitive assessment evaluations, broader availability of genetic testing for assessing Alzheimer’s risk, and the blending of multi-modal diagnostic strategies.
Get A Free Sample Report With In-Depth Market Insights:
Alzheimer’s Disease Diagnostic Market Growth Drivers: What’s Behind The Acceleration?
The escalating prevalence of chronic diseases is anticipated to fuel the expansion of the Alzheimer’s disease diagnostic market. This is because chronic conditions like cardiovascular disease, diabetes, and hypertension are strongly linked to an elevated risk of Alzheimer’s and other forms of dementia, thereby increasing the necessity for early and precise diagnostic tools. A significant contributor to the rise in chronic illnesses is the growing adoption of sedentary lifestyles, with extensive epidemiological studies consistently demonstrating higher rates of conditions such as diabetes and cardiovascular disease in physically inactive groups. Alzheimer’s diagnostics play a crucial role in supporting healthcare systems by allowing for prompt detection, enabling timely medical interventions, and guiding patient care to decelerate disease progression. For example, in November 2023, data from Heritage Health Services, a US-based nonprofit organization dedicated to healthcare research, indicated that 6.7 million Americans aged 65 or older were living with Alzheimer’s dementia. The prevalence notably increased with age: 5.0% for those 65–74 years old, 13.1% for 75–84 years, and 33.3% for individuals 85+ years. This figure is expected to climb to nearly 13 million by 2050. Consequently, the rising incidence of chronic diseases is a key factor propelling the growth of the Alzheimer’s disease diagnostic market.
Alzheimer’s Disease Diagnostic Market Breakdown By Product Type And Application
The alzheimer’s disease diagnostic market covered in this report is segmented –
1) By Type: Triage, Diagnosis, Screening
2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests
3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center
Subsegments:
1) By Triage: Cognitive Testing, Imaging Techniques
2) By Diagnosis: Biomarker Testing, Neuroimaging
3) By Screening: Neuropsychological Testing, Genetic Testing
Alzheimer’s Disease Diagnostic Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies in the alzheimer’s disease diagnostic market are concentrating on enhancing blood-based biomarker tests, which are anticipated to simplify the diagnostic process for Alzheimer’s disease, decreasing reliance on more invasive procedures and improving patients’ access to timely treatment. For instance, in October 2023, Quanterix, a US-based biotechnology research company, launched the LucentAD p-Tau 217 test, a blood-based biomarker for Alzheimer’s pathology exhibiting clinical sensitivity and specificity. Traditional methods for cerebrospinal fluid (CSF) biomarkers, including positron emission tomography (PET) or lumbar puncture, are both expensive, intrusive, and not widely accessible. Moreover, this test combines Quanterix’s ultra-sensitive SimoaÒ technology with J&J Innovative Medicine’s well-tested p-Tau 217 antibodies to deliver excellent accuracy and a simpler process.
Alzheimer’s Disease Diagnostic Market Company Landscape And Competitive Strategy
Major companies operating in the alzheimer’s disease diagnostic market are Hoffmann-La Roche, Eli Lilly and Company, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Lantheus, Quanterix, C2N Diagnostics, Sysmex, Royal Philips, Bruker Corporation, Revvity, Alamar Biosciences, ADx Neurosciences, Randox Laboratories, DiaSorin, Shenzhen Mindray Bio-Medical Electronics, Nipro Corporation, Canon Inc, Hitachi Ltd, Eisai Co Ltd
View The Full Alzheimer’s Disease Diagnostic Market Report:
Alzheimer’s Disease Diagnostic Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the alzheimer’s disease diagnostic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
